Utilising High Throughput Process Development (HTPD) and Design of Experiment (DoE) to Optimise the Pharmaron Gene Therapy Platform

At Pharmaron, we have successfully developed a flexible process for AAV production using a high-throughput development platform and Design of Experiment (DoE) techniques. This approach enables precise tuning of critical parameters, including loading density, residence time, and pH, to create high-quality, low-impurity AAV products tailored to specific therapeutic needs.

By leveraging advanced robotics, cutting-edge analytics (e.g., ELISA, DLS), and a streamlined process, Pharmaron accelerates development timelines while optimizing product yields and reducing resource requirements. This innovative platform ensures robust, fast solutions for gene therapy product development.